All Stories

  1. SISPA-Seq for rapid whole genome surveys of bacterial isolates
  2. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases
  3. First Report of an OXA-48-Producing Multidrug-Resistant Proteus mirabilis Strain from Gaza, Palestine
  4. Multicenter Evaluation of Candida QuickFISH BC for Identification of Candida Species Directly from Blood Culture Bottles
  5. Complete Sequence of ablaKPC-Harboring Cointegrate Plasmid Isolated from Escherichia coli
  6. Fulminant endocarditis and disseminated infection caused by carbapenem-resistantAcinetobacter baumanniiin a renal-pancreas transplant recipient
  7. Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae Reveal Multiple Pathways of Resistance
  8. Erratum for Wright et al., Population Structure of KPC-Producing Klebsiella pneumoniae Isolates from Midwestern U.S. Hospitals
  9. Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine
  10. Extensively Drug-Resistant Pseudomonas aeruginosa Isolates ContainingblaVIM-2and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio
  11. Identification of Occult Fusobacterium nucleatum Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry
  12. Population Structure of KPC-Producing Klebsiella pneumoniae Isolates from Midwestern U.S. Hospitals
  13. Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network
  14. Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae
  15. Comparative Genomic Analysis of KPC-Encoding pKpQIL-Like Plasmids and Their Distribution in New Jersey and New York Hospitals
  16. Molecular Survey of the Dissemination of TwoblaKPC-Harboring IncFIA Plasmids in New Jersey and New York Hospitals
  17. New Insights into Dissemination and Variation of the Health Care-Associated Pathogen Acinetobacter baumannii from Genomic Analysis
  18. Complete Sequence of a KPC-Producing IncN Multidrug-Resistant Plasmid from an Epidemic Escherichia coli Sequence Type 131 Strain in China
  19. Complete Nucleotide Sequence of ablaKPC-Harboring IncI2 Plasmid and Its Dissemination in New Jersey and New York Hospitals
  20. Antimicrobial-resistantStreptococcus pneumoniae: trends and management
  21. The Potential of Human Nasal Colonization withStreptococcus pneumoniaeas a Universal Pneumococcal Vaccine
  22. Complete Sequence of ablaKPC-2-Harboring IncFIIK1Plasmid from a Klebsiella pneumoniae Sequence Type 258 Strain
  23. Complete Nucleotide Sequences ofblaKPC-4- andblaKPC-5-Harboring IncN and IncX Plasmids from Klebsiella pneumoniae Strains Isolated in New Jersey
  24. Longitudinal Analysis of the Temporal Evolution of Acinetobacter baumannii Strains in Ohio, USA, by Using Rapid Automated Typing Methods
  25. "Silent" Dissemination of Klebsiella pneumoniae Isolates Bearing K. pneumoniae Carbapenemase in a Long-term Care Facility for Children and Young Adults in Northeast Ohio
  26. Pneumonia Due to Drug-Resistant Streptococcus pneumoniae
  27. Partial Excision ofblaKPCfrom Tn4401in Carbapenem-Resistant Klebsiella pneumoniae
  28. Antimicrobial Activity of B-Lock against Bacterial and Candida spp. Causing Catheter-Related Bloodstream Infections
  29. Are We Ready for Novel Detection Methods to Treat Respiratory Pathogens in Hospital-Acquired Pneumonia?
  30. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii
  31. Emergence of Linezolid-ResistantStaphylococcus aureusafter Prolonged Treatment of Cystic Fibrosis Patients in Cleveland, Ohio
  32. Novel bis-indole agents active against multidrug-resistant Acinetobacter baumannii
  33. Use of Vaporized Hydrogen Peroxide Decontamination during an Outbreak of Multidrug-Resistant Acinetobacter baumannii Infection at a Long-Term Acute Care Hospital
  34. Evaluation of Updated Interpretative Criteria for CategorizingKlebsiella pneumoniaewith Reduced Carbapenem Susceptibility
  35. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia
  36. Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes
  37. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination
  38. Evaluation of a Commercial Microarray System for Detection of SHV-, TEM-, CTX-M-, and KPC-Type  -Lactamase Genes in Gram-Negative Isolates
  39. Serotypes And Antimicrobial Susceptibility Of Streptococcus Pneumoniae Isolates From FOCUS 1 And 2, Two International Trials Of Ceftaroline In Patients Hospitalized For Community-acquired Bacterial Pneumonia
  40. In Vitro Activity of Fosfomycin against blaKPC-Containing Klebsiella pneumoniae Isolates, Including Those Nonsusceptible to Tigecycline and/or Colistin
  41. Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials
  42. Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System
  43. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA
  44. Mechanisms of Resistance in Haemophilus influenzae and Moraxella catarrhalis
  45. Emergence of Streptococcus pneumoniae Serotypes 19A, 6C, and 22F and Serogroup 15 in Cleveland, Ohio, in Relation to Introduction of the Protein‐Conjugated Pneumococcal Vaccine
  46. Occurrence, Distribution, and Origins of Streptococcus pneumoniae Serotype 6C, a Recently Recognized Serotype
  47. Antimicrobial-resistantStreptococcus pneumoniae: trends and management
  48. Presence of Plasmid-Mediated Quinolone Resistance in Klebsiella pneumoniae Isolates Possessing blaKPC in the United States
  49. Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics
  50. Antimicrobial Resistance in Haemophilus influenzae
  51. Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility
  52. Analysis of Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center
  54. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains
  55. Macrolide Resistance in Streptococcus pneumoniae: Clonality and Mechanisms of Resistance in 24 Countries
  56. Antianaerobic Activity of a Novel Fluoroquinolone, WCK 771, Compared to Those of Nine Other Agents
  57. Streptococcus pneumoniae: Epidemiology and patterns of resistance
  58. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998–2001 U.S. Surveillance Study
  59. Antimicrobial Resistance: Challenges and Solutions
  60. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections
  61. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns
  62. Antimicrobial Resistance: Challenges and Solutions
  63. Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae in Sao Paulo, Brazil from 1996 to 2000
  64. Four Antibiotic‐Resistant Streptococcus pneumoniae Clones Unrelated to the Pneumococcal Conjugate Vaccine Serotypes, Including 2 New Serotypes, Causing Acute Otitis Media in Southern Israel
  65. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges
  66. Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci
  67. Postantibiotic Effects of Daptomycin against 14 Staphylococcal and Pneumococcal Clinical Isolates
  68. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children
  69. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents
  70. Time-Kill Studies of the Antianaerobe Activity of Garenoxacin Compared with Those of Nine Other Agents
  71. Cefotaxime-Resistant Bacteria Colonizing Older People Admitted to an Acute Care Hospital
  72. Postantibiotic Effects of Garenoxacin (BMS-284756) against 12 Gram-Positive or -Negative Organisms
  73. Effects of an Efflux Mechanism and Ribosomal Mutations on Macrolide Susceptibility of Haemophilus influenzae Clinical Isolates
  74. Antianaerobe Activity of RBX 7644 (Ranbezolid), a New Oxazolidinone, Compared with Those of Eight Other Agents
  75. Use of Appropriate Breakpoints in Antimicrobial Surveillance Studies
  76. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate
  77. In Vivo Veritas: In Vitro Macrolide Resistance in Systemic Streptococcus pneumoniae Infections Does Result in Clinical Failure
  78. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin
  79. Antimicrobial guidelines for the treatment of acute bacterial rhinosinusitis in immunocompetent children
  80. Antipneumococcal Activity of BMS 284756 Compared to Those of Six Other Agents
  81. Antipneumococcal Activity of Ertapenem (MK-0826) Compared to Those of Other Agents
  82. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999–2000
  83. Pneumococcal Conjugate Vaccine Serotypes of Streptococcus pneumoniae Isolates and the Antimicrobial Susceptibility of Such Isolates in Children with Otitis Media
  84. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters
  85. High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda
  86. Comparative Antianaerobic Activity of BMS 284756
  87. Assumed versus Approved Breakpoints
  88. Mediterranean clone of penicillin-susceptible, multidrug-resistant serotype 6B Streptococcus pneumoniae in Greece, Italy and Israel
  89. Establishing Criteria for Assessment of Efficacy of Antimicrobial Agents in Acute Otitis Media
  90. Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries
  91. Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods
  92. Enterobacter Species Bacteremia: Factors Predictive of Mortality at a Tertiary Care Institution
  93. Serotypes and antimicrobial susceptibility in clinical isolates of Haemophilus influenzae from Korean children in prevaccination era
  94. Prevalence of mefE, erm and tet(M) genes in Streptococcus pneumoniae strains from central Italy
  95. Spread of Drug‐Resistant Streptococcus pneumoniae in Asian Countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study
  96. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices
  97. Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America
  98. Streptococcus pneumoniae: Activity of newer agents against penicillin-resistant strains
  99. Genetic Analysis of Serotype 23F Streptococcus pneumoniae Isolates from Several Countries by Penicillin-Binding Protein Gene Fingerprinting and Pulsed-Field Gel Electrophoresis
  100. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group
  101. Antimicrobial susceptibility of Streptococcus pneumoniae from children attending day-care lefts in a central Italian city
  102. Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update
  103. Norwegian Scabies and a Toxic Shock Syndrome Toxin 1–Producing Strain of Staphylococcus aureus Endocarditis in a Patient with Trisomy 21
  104. Spread of Multidrug‐Resistant Streptococcus pneumoniae in South Korea
  105. Resistance Patterns of Streptococcus pneumoniae from Carriers Attending Day‐Care Centers in Southwestern Greece
  106. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media
  107. Efficacy of amoxicillin/clavulanate for acute otitis media: relation to Streptococcus pneumoniae susceptibility
  108. Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patients
  109. Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and a human monocyte in-vitro infection model
  110. Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci
  111. Activity of CP 99, 219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepaloxacin against penicillin-susceptible and -resistant pneumococci
  112. Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.
  113. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
  114. Anti-Mycobacterium avium Activity of Quinolones: In Vitro Activities
  115. Anti-Mycobacterium avium activity of quinolones: in vitro activities.
  116. Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studies.
  118. Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for Gram-positive corneal pathogens
  119. Treatment and Diagnosis of Infections Caused by Drug-Resistant Streptococcus pneumoniae
  120. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
  121. Topical fluoroquinolones: Antimicrobial activity andin vitrocorneal epithelial toxicity
  122. Treatment of experimental Salmonella typhimurium infection in mice with fleroxacin.
  123. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis.
  124. In-vitro activity of erythromycin, roxithromycin and CP 62993 against common paediatric pathogens
  125. Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice
  126. Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads
  127. Infection caused by vancomycin-resistant Streptococcus sanguis II.
  128. Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis
  129. Susceptibility of group B streptococci to 16 beta-lactam antibiotics, including new penicillin and cephalosporin derivatives.
  130. Comparative efficacies of ceftriaxone, moxalactam, and ampicillin in experimental Salmonella typhimurium infection.
  131. Penicillin susceptibility testing of gonococci by disc diffusion
  132. Multiple-antibiotic resistance—now the pneumococcus